Skip to content
Opens in a new window
For Oncology Nurses: Non-Small Cell Lung Cancer with a ROS1 Fusion — An Interview with Dr Alexander E Drilon
30 September 2026

For Oncology Nurses: Non-Small Cell Lung Cancer with a ROS1 Fusion — An Interview with Dr Alexander E Drilon

Lung Cancer Update

About

Featuring an interview with Dr Alexander E Drilon, including the following topics:

    Overview of targetable biomarkers in lung cancer (0:00)Biomarker testing for genomic alterations in lung cancer (5:24)Overview of ROS1 alterations in lung cancer (13:44)Efficacy data with ROS1 inhibitors for lung cancer (17:02)Safety data with ROS1 inhibitors for lung cancer (21:15)Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56)Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16)Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)

NCPD information and select publications